Transient receptor potential channel 4/5 inhibitor - Bristol-Myers Squibb - to be REUSED
Alternative Names: TRPC4/5 inhibitor - Bristol-Myers SquibbLatest Information Update: 28 Mar 2025
At a glance
- Originator Bristol-Myers Squibb
- Class Anxiolytics; Mood stabilisers
- Mechanism of Action TRPC4 cation channel inhibitors; TRPC5 cation channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Anxiety disorders; Mood disorders
Most Recent Events
- 12 Jun 2024 Phase-I clinical trials in Anxiety disorders in USA (unspecified route), prior to June 2024 (Bristol-Myers Squibb pipeline, June 2024)
- 12 Jun 2024 Phase-I clinical trials in Mood disorders in USA (unspecified route), prior to June 2024 (Bristol-Myers Squibb pipeline, June 2024)
- 12 Jun 2024 Preclinical trials in Anxiety disorders in USA (unspecified route), prior to June 2024 (Bristol-Myers Squibb pipeline, June 2024)